{"slideshow_credits": null, "snippet": "The Food and Drug Administration called Kalydeco a \u201cbreakthrough therapy\u201d because it treats the underlying cause of the genetic disease, rather than just the symptoms.", "abstract": "Food and Drug Administration approves Kalydeco, developed by Vertex Pharmaceuticals, the first drug that treats an underlying cause of cystic fibrosis, rather than just the symptoms.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2012/02/01/business/fda-approves-cystic-fibrosis-drug.html", "lead_paragraph": "The Food and Drug Administration called Kalydeco a \u201cbreakthrough therapy\u201d because it treats the underlying cause of the genetic disease, rather than just the symptoms.", "headline": {"seo": "F.D.A. Approves Cystic Fibrosis Drug", "main": "F.D.A. Approves New Cystic Fibrosis Drug", "print_headline": "F.D.A. Approves New Cystic Fibrosis Drug"}, "_id": "53a97dfe38f0d85886bc4063", "word_count": "703", "multimedia": [], "pub_date": "2012-02-01T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Cystic Fibrosis", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Food and Drug Administration", "name": "organizations", "is_major": "N", "rank": "3"}, {"value": "Vertex Pharmaceuticals Inc", "name": "organizations", "is_major": "Y", "rank": "4"}, {"value": "Regulation and Deregulation of Industry", "name": "subject", "is_major": "N", "rank": "5"}], "blog": [], "subsection_name": null, "type_of_material": "News"}